Ginkgo Bioworks Holdings (DNA) Aktievy
Ginkgo Bioworks Holdings, Inc, tillsammans med sina dotterbolag, utvecklar en plattform för cellteknik i USA. Mer information
| Snöflinga Score | |
|---|---|
| Värdering | 0/6 |
| Framtida tillväxt | 0/6 |
| Tidigare resultat | 0/6 |
| Finansiell hälsa | 5/6 |
| Utdelningar | 0/6 |
DNA Community Fair Values
Create NarrativeSee what 61 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Ginkgo Bioworks Holdings, Inc. Konkurrenter
Prishistorik och prestanda
| Historiska aktiekurser | |
|---|---|
| Aktuell aktiekurs | US$9.04 |
| 52 veckors högsta | US$17.58 |
| 52 veckors lägsta | US$5.37 |
| Beta | 1.8 |
| 1 månads förändring | 7.49% |
| 3 månaders förändring | 26.08% |
| 1 års förändring | 5.98% |
| 3 års förändring | -85.79% |
| 5 års förändring | -97.72% |
| Förändring sedan börsintroduktionen | -97.77% |
Senaste nyheter och uppdateringar
Seeking Alpha • May 13
Ginkgo Bioworks: Another Lost Year
Summary Ginkgo Bioworks (DNA) reported Q1 revenues of $19.5M, down nearly 50% year-over-year and badly missing street estimates even after Biosecurity adjustments. Management is pivoting to autonomous labs but refuses to provide revenue guidance, causing analyst estimates to fall further. DNA continues to burn significant cash, with Q1 cash burn at $49M and 2026 guidance of $125M–$150M, leaving $373M in cash and no debt but weakening flexibility. Read the full article on Seeking AlphaAnalysartikel • May 13
Newsflash: Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Analysts Have Been Trimming Their Revenue Forecasts
The analysts covering Ginkgo Bioworks Holdings, Inc. ( NYSE:DNA ) delivered a dose of negativity to shareholders today...
Uppdatering av berättelse • May 09
DNA: Weaker Outlook Will Hinge On Uncertain Autonomous Lab Monetization
Analysts have lowered their average price target on Ginkgo Bioworks Holdings to $5 from $9, citing the impact of the company's biosecurity divestiture on guidance clarity and noting that they are looking for better visibility into its autonomous lab buildout and monetization efforts. Analyst Commentary Analysts are reassessing Ginkgo Bioworks Holdings after the biosecurity divestiture and the reset to a US$5 price target, focusing more tightly on cash usage and the path to monetizing its autonomous lab capabilities.Recent updates
Seeking Alpha • May 13
Ginkgo Bioworks: Another Lost Year
Summary Ginkgo Bioworks (DNA) reported Q1 revenues of $19.5M, down nearly 50% year-over-year and badly missing street estimates even after Biosecurity adjustments. Management is pivoting to autonomous labs but refuses to provide revenue guidance, causing analyst estimates to fall further. DNA continues to burn significant cash, with Q1 cash burn at $49M and 2026 guidance of $125M–$150M, leaving $373M in cash and no debt but weakening flexibility. Read the full article on Seeking AlphaAnalysartikel • May 13
Newsflash: Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Analysts Have Been Trimming Their Revenue Forecasts
The analysts covering Ginkgo Bioworks Holdings, Inc. ( NYSE:DNA ) delivered a dose of negativity to shareholders today...Uppdatering av berättelse • May 09
DNA: Weaker Outlook Will Hinge On Uncertain Autonomous Lab Monetization
Analysts have lowered their average price target on Ginkgo Bioworks Holdings to $5 from $9, citing the impact of the company's biosecurity divestiture on guidance clarity and noting that they are looking for better visibility into its autonomous lab buildout and monetization efforts. Analyst Commentary Analysts are reassessing Ginkgo Bioworks Holdings after the biosecurity divestiture and the reset to a US$5 price target, focusing more tightly on cash usage and the path to monetizing its autonomous lab capabilities.Analysartikel • Apr 30
Will Ginkgo Bioworks Holdings (NYSE:DNA) Spend Its Cash Wisely?
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Uppdatering av berättelse • Apr 24
DNA: Autonomous Labs And AI Execution Will Drive Multi Year Upside Potential
Analysts have reduced their price target on Ginkgo Bioworks Holdings to $5 from $9, citing the impact of the company's biosecurity divestiture on guidance and a desire for clearer progress in building and monetizing its autonomous labs. Analyst Commentary While the latest price target move reflects caution around the divestiture and reduced visibility, some Bullish analysts still see potential upside if Ginkgo can translate its platform into clearer revenue traction and disciplined cash use.
Uppdatering av berättelse • Apr 10
DNA: Biosecurity Exit And Cash Burn Will Pressure Autonomous Lab Payoff
Analysts have reduced their price target on Ginkgo Bioworks Holdings to $5 from $9, citing the sale of the biosecurity business and a desire for clearer progress on building and monetizing autonomous labs as key reasons for the reset. Analyst Commentary Bearish analysts are signaling a more cautious stance on Ginkgo Bioworks Holdings following the reduction in the price target to US$5 from US$9.Uppdatering av berättelse • Mar 27
DNA: Future Cash Burn And Autonomous Lab Execution Will Drive Downside Risk
Narrative Update on Ginkgo Bioworks Holdings Analysts have reduced their price target on Ginkgo Bioworks Holdings to $5 from $9, citing the biosecurity divestiture, a shift to cash burn guidance, and a focus on clearer progress in building and monetizing autonomous labs as key factors behind the change. Analyst Commentary Recent research updates highlight a shift toward more cautious expectations around Ginkgo Bioworks Holdings, with price targets reset lower and a tighter focus on execution risks tied to the business model and cost profile.Uppdatering av berättelse • Mar 13
DNA: Future Returns Will Hinge On Monetizing Autonomous Labs By 2026
Analysts have trimmed their average price target for Ginkgo Bioworks Holdings, with cuts from $14 to $12 and from $9 to $5, reflecting reduced revenue growth assumptions, a slightly lower fair value estimate, and a higher discount rate as they wait for clearer progress on monetizing autonomous labs after the biosecurity divestiture. Analyst Commentary Bullish Takeaways Bullish analysts still see enough long term potential to maintain positive ratings, even as they trim price targets to US$12 from US$14.Uppdatering av berättelse • Feb 22
DNA: 2026 Guidance Will Anchor Sector Recovery And Support Multi-Year Upside
Narrative Update Analysts have trimmed their 12-month price target on Ginkgo Bioworks Holdings to $12 from $14, citing updated views on sector recovery, clearer multi year frameworks, and multiple avenues for upside within what they see as more derisked growth assumptions. Analyst Commentary Bullish analysts trimming the 12 month price target to US$12 from US$14 are framing the move as a recalibration within the broader diagnostic tools group rather than a shift away from their positive view on Ginkgo Bioworks Holdings.Uppdatering av berättelse • Feb 08
DNA: 2026 Guidance And Sector Recovery Will Anchor Multi-Year Upside Potential
Analysts have trimmed their price target on Ginkgo Bioworks Holdings to $12 from $14, citing updated sector assumptions and a preference for companies with clear multi year frameworks and multiple potential upside drivers to growth expectations. Analyst Commentary Bullish analysts are keeping a constructive stance on Ginkgo Bioworks Holdings even as they reset expectations with a lower price target.Uppdatering av berättelse • Jan 24
DNA: 2026 Guidance And Sector Recovery Could Unlock Multi-Year Upside
Analysts have trimmed their price target on Ginkgo Bioworks Holdings to US$12.00 from US$14.00, citing updated assumptions on growth, margins and future P/E multiples. They also point to the importance of clear multi year frameworks and multiple avenues for potential upside within a recovering sector.Uppdatering av berättelse • Jan 10
DNA: Future Returns Will Rely On Multi Year Execution And Cost Discipline
Analysts have trimmed their price target on Ginkgo Bioworks Holdings to $12 from $14, citing a reset in fair value assumptions to $10 and updated views on growth and margins, while still emphasizing the importance of clear multi year frameworks and multiple avenues for potential upside as sector sentiment improves. Analyst Commentary Bullish Takeaways Bullish analysts view the reset to a US$12 price target as aligning the stock more closely with updated fair value assumptions, which can reduce the risk of expectations getting too far ahead of execution.Uppdatering av berättelse • Dec 15
DNA Could Benefit From Government And Pharma Partnerships Over Coming Years
Analysts have trimmed their price target on Ginkgo Bioworks Holdings by about 12 percent to an updated implied fair value of approximately $14.00 per share, reflecting a higher discount rate despite improved expectations for revenue growth, profit margins, and a lower future price to earnings multiple. What's in the News Partnered with Deep Origin on a 4.5 year ARPA H funded CATALYST program project to build a computational drug safety platform using Ginkgo's Datapoints perturbation profiling data to train AI models across multiple cell and tissue types (ARPA H program announcement).Analysartikel • Nov 17
Why Investors Shouldn't Be Surprised By Ginkgo Bioworks Holdings, Inc.'s (NYSE:DNA) 39% Share Price Plunge
The Ginkgo Bioworks Holdings, Inc. ( NYSE:DNA ) share price has fared very poorly over the last month, falling by a...Uppdatering av berättelse • Nov 07
DNA: Future Profitability Will Depend On Cost Controls And Execution
Analysts have raised their price target for Ginkgo Bioworks shares from $6 to $9, citing stronger-than-expected second quarter results and improved cost controls. However, they caution that visibility into long-term growth and EBITDA profitability remains limited.Uppdatering av berättelse • Oct 24
Cost Reductions And New Partnerships Will Shape Profit Prospects By 2026
Analysts have raised their price target for Ginkgo Bioworks Holdings from $6 to $9, citing a significant revenue beat in the second quarter and faster-than-anticipated cost reductions. However, they still note some uncertainty about profitability targets for 2026.Uppdatering av berättelse • Oct 10
Life Sciences Automation Will Stagnate Amid Regulatory Challenges
Analysts have raised their price target for Ginkgo Bioworks Holdings from $11.33 to $12.00 per share, citing a notable Q2 topline beat and improved cost management as key drivers for the revised outlook. Analyst Commentary Following the recent performance and guidance update, analyst opinions on Ginkgo Bioworks Holdings remain mixed, reflecting both the company’s progress and outstanding challenges.Analysartikel • Oct 03
Ginkgo Bioworks Holdings, Inc.'s (NYSE:DNA) Shares Climb 45% But Its Business Is Yet to Catch Up
Ginkgo Bioworks Holdings, Inc. ( NYSE:DNA ) shares have had a really impressive month, gaining 45% after a shaky period...Uppdatering av berättelse • Aug 26
Life Sciences Automation Will Stagnate Amid Regulatory Challenges
Analysts have raised Ginkgo Bioworks Holdings’ price target to $11.33 on the back of a strong Q2 topline beat and accelerated cost reductions, though concerns persist over EBITDA breakeven achievability and medium-term growth visibility. Analyst Commentary Bullish analysts highlight a significant Q2 topline beat driven by faster-than-expected cost reductions.Uppdatering av berättelse • Aug 10
Life Sciences Automation Will Stagnate Amid Regulatory Challenges
The notable increase in Ginkgo Bioworks' consensus price target reflects significantly improved net profit margins and a marked decline in future P/E, resulting in a fair value revision from $8.67 to $10.33. What's in the News Ginkgo Bioworks reaffirmed its full-year 2025 revenue guidance at $167 million to $187 million.Analysartikel • Jun 25
Ginkgo Bioworks Holdings, Inc.'s (NYSE:DNA) 31% Price Boost Is Out Of Tune With Revenues
Despite an already strong run, Ginkgo Bioworks Holdings, Inc. ( NYSE:DNA ) shares have been powering on, with a gain of...Analysartikel • May 09
Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) First-Quarter Results: Here's What Analysts Are Forecasting For This Year
As you might know, Ginkgo Bioworks Holdings, Inc. ( NYSE:DNA ) just kicked off its latest quarterly results with some...Analysartikel • Apr 27
Ginkgo Bioworks Holdings, Inc.'s (NYSE:DNA) Shares Climb 28% But Its Business Is Yet to Catch Up
Those holding Ginkgo Bioworks Holdings, Inc. ( NYSE:DNA ) shares would be relieved that the share price has rebounded...
Ny berättelse • Mar 27
Biopharma Demand Will Boost Automation And Data Services
Shifting towards tools like Ginkgo Automation platform addresses biopharma AI data demand, enhancing revenue through diversification.Analysartikel • Mar 01
These Analysts Think Ginkgo Bioworks Holdings, Inc.'s (NYSE:DNA) Sales Are Under Threat
The latest analyst coverage could presage a bad day for Ginkgo Bioworks Holdings, Inc. ( NYSE:DNA ), with the analysts...Seeking Alpha • Feb 27
2025 Is Make Or Break For Ginkgo Bioworks
Summary Ginkgo Bioworks' restructuring has resulted in a dramatic reduction in cash burn in recent quarters. Ginkgo remains a long way from breakeven though and growth is expected to be poor in 2025. Unless Ginkgo can demonstrate continuous progress in 2025, its stock is likely to remain under pressure due to its shrinking cash runway. Read the full article on Seeking AlphaAnalysartikel • Feb 13
Revenues Not Telling The Story For Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) After Shares Rise 39%
Ginkgo Bioworks Holdings, Inc. ( NYSE:DNA ) shares have continued their recent momentum with a 39% gain in the last...Seeking Alpha • Jan 30
Ginkgo Bioworks: Declining Core Revenue And High Cash Burn Echo Amyris' Path
Summary Ginkgo Bioworks faces ongoing revenue declines and high cash burn, despite cost-cutting efforts and partnerships with major firms like Pfizer and Merck. The company's Q3 2024 revenue was inflated by non-cash deferred revenue, masking a true 21% Y/Y revenue decrease, raising concerns about sustainable growth. Ginkgo's broad market approach and high-risk synthetic biology ventures, similar to Amyris, make profitability uncertain, despite a strong cash position extending into mid-2026. Maintain a "sell" rating on DNA due to overvaluation, ongoing losses, and dilution, with potential breakthroughs and faster commercial adoption as key risks to this stance. Read the full article on Seeking AlphaAnalysartikel • Nov 15
Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Just Released Its Third-Quarter Earnings: Here's What Analysts Think
A week ago, Ginkgo Bioworks Holdings, Inc. ( NYSE:DNA ) came out with a strong set of third-quarter numbers that could...Seeking Alpha • Nov 13
Ginkgo Bioworks: Not Enough Progress
Summary Ginkgo Bioworks reported mixed Q3 results, with a $45 million one-time revenue boost masking underlying revenue growth issues. Despite cost-cutting efforts, Ginkgo continues to report large losses, and $325 million of cash was burned in the first nine months of 2023. The balance sheet is weakening, and long-term revenue estimates have continued to move lower. Read the full article on Seeking AlphaAnalysartikel • Oct 04
Revenues Tell The Story For Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) As Its Stock Soars 33%
Ginkgo Bioworks Holdings, Inc. ( NYSE:DNA ) shareholders are no doubt pleased to see that the share price has bounced...Seeking Alpha • Aug 22
Ginkgo Bioworks: Here Comes The Test
Summary Ginkgo Bioworks has struggled with missed revenue targets, leading to a significant decline in share value. The recent Q2 report showed a 30% decrease in total revenues, with cost structure still a major issue for the company. Balance sheet weakening as cash reserves decrease, putting pressure on working capital and financial flexibility. Read the full article on Seeking AlphaAnalysartikel • Aug 16
The Price Is Right For Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Even After Diving 27%
Unfortunately for some shareholders, the Ginkgo Bioworks Holdings, Inc. ( NYSE:DNA ) share price has dived 27% in the...Seeking Alpha • Jun 25
Ginkgo Bioworks: Losing A Major Supporter
Summary Cathie Wood and Ark Invest have started selling Ginkgo shares, adding to recent selling pressure. Ginkgo revenue estimates have dropped further after the latest guidance cut from management. Despite the falling stock price, Ginkgo still faces bleak growth prospects, high valuation, and the potential for a reverse split announcement. Read the full article on Seeking AlphaAnalysartikel • Jun 18
Ginkgo Bioworks Holdings, Inc.'s (NYSE:DNA) Share Price Is Still Matching Investor Opinion Despite 47% Slump
Unfortunately for some shareholders, the Ginkgo Bioworks Holdings, Inc. ( NYSE:DNA ) share price has dived 47% in the...Analysartikel • May 11
Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
There's been a major selloff in Ginkgo Bioworks Holdings, Inc. ( NYSE:DNA ) shares in the week since it released its...Seeking Alpha • May 10
Ginkgo Bioworks: Broken Narrative
Summary Ginkgo Bioworks' first quarter earnings were weak, with revenue and guidance falling well short of expectations. The company is shifting its business model away from ownership of IP and participation in downstream value, undermining the bull case. Ginkgo now appears to be moving towards a traditional CRO business model and should be valued as such. Read the full article on Seeking AlphaAnalysartikel • Apr 26
Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Stocks Pounded By 27% But Not Lagging Industry On Growth Or Pricing
To the annoyance of some shareholders, Ginkgo Bioworks Holdings, Inc. ( NYSE:DNA ) shares are down a considerable 27...Analysartikel • Mar 06
Newsflash: Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Analysts Have Been Trimming Their Revenue Forecasts
The analysts covering Ginkgo Bioworks Holdings, Inc. ( NYSE:DNA ) delivered a dose of negativity to shareholders today...Aktieägarnas avkastning
| DNA | US Life Sciences | US Marknad | |
|---|---|---|---|
| 7D | 9.8% | -2.2% | -1.8% |
| 1Y | 6.0% | 8.4% | 23.3% |
Avkastning vs industri: DNA presterade sämre än US Life Sciences branschen som gav 8.4 % under det senaste året.
Avkastning vs Marknaden: DNA presterade sämre än US marknaden som gav 23.3 % under det senaste året.
Prisvolatilitet
| DNA volatility | |
|---|---|
| DNA Average Weekly Movement | 13.1% |
| Life Sciences Industry Average Movement | 8.5% |
| Market Average Movement | 7.3% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stabil aktiekurs: DNA s aktiekurs har varit volatil under de senaste 3 månaderna jämfört med marknaden för US.
Volatilitet över tid: DNA s veckovolatilitet ( 13% ) har varit stabil under det senaste året, men är fortfarande högre än 75 % av US aktier.
Om företaget
| Grundad | Anställda | VD OCH KONCERNCHEF | Webbplats |
|---|---|---|---|
| 2008 | 485 | Jason Kelly | www.ginkgo.bio |
Ginkgo Bioworks Holdings, Inc. utvecklar tillsammans med sina dotterbolag en plattform för cellteknik i USA. Verksamheten bedrivs genom segmenten Cell Engineering och Biosecurity. Företaget erbjuder lösningar för forskning och utveckling inom cellteknik samt cellteknikverktyg som omfattar funktionell genomik, antikroppsutveckling och utveckling av små molekyler, modeller för artificiell intelligens och omkonfigurerbara automationsvagnssystem på sin plattform för användning inom forskning, utveckling och kommersialisering av konstruerade organismer och produkter som härrör från dessa.
Ginkgo Bioworks Holdings, Inc. Sammanfattning av grunderna
| DNA grundläggande statistik | |
|---|---|
| Börsvärde | US$599.03m |
| Vinst(TTM) | -US$305.51m |
| Intäkter(TTM) | US$151.40m |
3.9x
P/S-förhållande-1.9x
P/E-förhållandeÄr DNA övervärderat?
Se Verkligt värde och värderingsanalysResultat & intäkter
| DNA resultaträkning (TTM) | |
|---|---|
| Intäkter | US$151.40m |
| Kostnad för intäkter | US$45.98m |
| Bruttovinst | US$105.42m |
| Övriga kostnader | US$410.93m |
| Intäkter | -US$305.51m |
Senast redovisade vinst
Mar 31, 2026
Nästa vinstdatum
n/a
| Vinst per aktie (EPS) | -4.68 |
| Bruttomarginal | 69.63% |
| Nettovinstmarginal | -201.79% |
| Skuld/egenkapitalförhållande | 0% |
Hur har DNA utvecklats på lång sikt?
Se historisk utveckling och jämförelseFöretagsanalys och finansiella data Status
| Uppgifter | Senast uppdaterad (UTC-tid) |
|---|---|
| Analys av företag | 2026/06/22 10:42 |
| Aktiekurs vid dagens slut | 2026/06/22 00:00 |
| Intäkter | 2026/03/31 |
| Årlig intjäning | 2025/12/31 |
Datakällor
Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.
| Paket | Uppgifter | Tidsram | Exempel US-källa |
|---|---|---|---|
| Företagets finansiella ställning | 10 år |
| |
| Analytikernas konsensusuppskattningar | +3 år |
|
|
| Marknadspriser | 30 år |
| |
| Ägarskap | 10 år |
| |
| Förvaltning | 10 år |
| |
| Viktiga utvecklingstendenser | 10 år |
|
* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.
Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.
Analysmodell och snöflinga
Detaljer om analysmodellen som används för att skapa denna rapport finns på vår Github-sida; vi har också guider om hur du använder våra rapporter och handledningar på Youtube.
Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.
Industri- och sektormått
Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.
Källor för analytiker
Ginkgo Bioworks Holdings, Inc. bevakas av 8 analytiker. 2 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.
| Analytiker | Institution |
|---|---|
| Michael Ryskin | BofA Global Research |
| Mark Massaro | BTIG |
| Matthew Sykes | Goldman Sachs |